Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) entered into an Agreement to acquire DMK Pharmaceuticals, Inc. on February 24, 2023. At the close of the merger, Eboo Versi, the current CEO of DMK, will assume the role of CEO and chairman of the combined company, David J. Marguglio, the current chief executive officer and President of Adamis, is expected to continue as President of the company and David C. Benedicto is expected to continue as the chief financial officer of the company. The transaction is subject to approval by the Adamis and DMK?s stockholders.

The transaction was approved by the boards of directors of both companies and expected to close during the second quarter of 2023. Raymond James Financial, Inc. (NYSE:RJF) acted as a financial advisor for Adamis Pharmaceuticals Corporation .